Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This study is a prospective open label, multicenter, phase II, window-of-opportunity
preoperative, single-agent trial.
This study aims to evaluate the efficacy, the safety and tolerability profile of bintrafusp
alfa in patients with histologically or cytologically confirmed squamous cell carcinoma of
the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of
primary surgery. Patients with a diagnosis of head and neck squamous cell carcinoma (HNSCC)
from unknown primary will not be enrolled.